Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 60+ key pharma and biotech companies are working on 60+ pipeline drugs in the Graft-Versus-Host Disease (GVHD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development […]
